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The sudden outbreak of severe acute respiratory syndrome (SARS) in 2002
prompted the establishment of a global scientiﬁc network subsuming most of the
traditional rivalries in the competitive ﬁeld of virology. Within months of the SARS
outbreak, collaborative work revealed the identity of the disastrous pathogen as
SARS-associated coronavirus (SARS-CoV). However, although the rapid identiﬁ-
cation of the agent represented an important breakthrough, our understanding of
the deadly virus remains limited. Detailed biological knowledge is crucial for the
development of eﬀective countermeasures, diagnostic tests, vaccines and antiviral
drugs against the SARS-CoV. This article reviews the present state of molecular
knowledge about SARS-CoV, from the aspects of comparative genomics, molecular
biology of viral genes, evolution, and epidemiology, and describes the diagnostic
tests and the anti-viral drugs derived so far based on the available molecular infor-
mation.
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Introduction
The ﬁrst SARS case was reported in late 2002 in
China’s Guangdong Province (1 ). The disease was
contagious and spreaded rapidly, resulting in a SARS
outbreak in Hong Kong in mid-February 2003, and
other outbreaks elsewhere in the world. At the end
of March 2003, a virus of the Coronaviridae family
was identiﬁed as the causative agent of the disease
(2 -4 ). This identiﬁcation has been conﬁrmed by the
World Health Organization, and the virus concerned
has been designated as the SARS-associated coro-
navirus (SARS-CoV). During the SARS outbreaks
in 2002 and 2003, SARS cases were identiﬁed in
19 countries, and in total 8,605 individuals became
infected, of whom 774 died (http://www.who.int/
csr/sars/country/table2003 09 23/en/).
In addition to its cost in human lives, the SARS
outbreak also had a great impact on the health care
system and economy of Hong Kong and other infected
regions. In Hong Kong, the estimated economic loss
was about HK$46 billion (US$5.9 billion; ref. 5 ). The
possibility that SARS-CoV transmission can occur be-
tween human beings without reinforcement from the
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animal reservoir (5 ) and the capability of the
virus to infect multiple cell types (6 ) and an-
imals (7 ) further increased the epidemiological
burden of the SARS pandemic. Although the
spread of the virus had seemed to be conﬁned by
July 2003 through rigorous quarantine measures
(http://www.who.int/csr/sars/country/table2003 09
23/en/), it may still be circulating in the animal
reservoir and it is impossible to say that it will not
return (8 -10 ). Because of this possibility, better mon-
itoring of SARS outbreaks through accurate diagnos-
tic tests and the development of eﬀective anti-viral
therapies are urgently required. These in turn depend
on better molecular knowledge about the SARS-CoV.
Such research is therefore of vital importance if the
community is to be properly prepared for a possible
recurrence of the SARS pandemic.
Molecular Biology of SARS-CoV
Molecular characterization of the
SARS-CoV genome
The etiological entity of a viral infection relies on both
molecular and traditional virological methods includ-
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ing serological techniques, virus isolation by cell cul-
ture, and electron microscopy (2 , 10 ). Both molecu-
lar approaches and conventional approaches were em-
ployed for the initial characterization of the SARS
pathogen (2 ). Peiris et al (2 ) ﬁrstly isolated the virus
from in vitro tissue culture and subsequently yielded a
646-bp genomic fragment by RT-PCR using degener-
ate primers, which showed more than 50% homology
to the RNA polymerase gene of bovine coronavirus
(BCV) and murine hepatitis virus (MHV). The use
of gene chip further conﬁrmed the coronavirus as a
possible cause of SARS (11 ).
Soon after the identiﬁcation of the SARS-CoV,
laboratories started to investigate the phylogenetic re-
lationship between the virus and the other members of
the same family through extensive comparison of their
genome sequences. In mid-April 2003, the British
Columbia Cancer Agency (BCCA) Genome Science
Center in Canada (12 ), the Center of Disease Control
in the United States (13 ) and the University of Hong
Kong (14 ) announced at nearly the same time that
the complete genome sequence of the SARS-CoV had
been isolated in the corresponding areas (15 ). The
results of independent sequencing of the SARS-CoV
genome all indicated that it was a polyadenylated ge-
nomic RNA of 29.7 Kb in length. Comparative anal-
ysis of the genome with other coronaviruses suggested
that the virus genome was very similar to previously
characterized coronaviruses, with the order (starting
from the N-terminal): replicase (R), spike (S), enve-
lope (E), membrane (M) and nucleocapsid (N) gene,
where there are few accessory genes or motifs span-
ning between the structural genes and at the 3′ UTR
(untranslated region), which may not be necessary for
viral replication (12 ). The replicase gene, with two
open reading frames (ORF) 1a and 1b, covering more
than two thirds of the genome, is predicted to encode
only two proteinases (12 -14 ) that regulate both the
replication of the positive-stranded genomic RNA and
the subsequent transcription of a nested set of eight
subgenomic (sg) mRNAs (Table 1; ref. 16 ), which is
a common transcription strategy adopted by coron-
avirus members (17 -21 ).
Table 1 Features of SARS-CoV Genome Sequence and Subgenomic Transcripts
g/sg mRNA ORF Start-End No. of a.a. No. of Bases Frame
Thiel et al. Zeng et al. Marra et al. Rota et al.
mRNA 1 ORF 1a ORF 1a ORF 1a ORF 1a 265-13,398 4,382 13,149 +1
mRNA 1 ORF 1b ORF 1b ORF 1b ORF 1b 13,398-21,485 2,628 7,887 +3
mRNA 2 S protein S protein S protein S protein 21,492-25,259 1,255 3,768 +3
mRNA 3 ORF 3a X1 ORF 3 X1 25,268-26,092 274 825 +2
mRNA 3 ORF 3b N/R ORF 4 X2 25,689-26,153 154 465 +3
mRNA 4 E protein N/R E protein E protein 26,117-26,347 76 231 +2
mRNA 5 M protein M protein M protein M protein 26,398-27,063 221 666 +1
mRNA 6 ORF 6 N/R ORF 7 X3 27,074-27,265 63 192 +2
mRNA 7 ORF 7a X2 ORF 8 X4 27,273-27,641 122 369 +3
mRNA 7 ORF 7b N/R ORF 9 N/R 27,638-27,772 44 135 +2
mRNA 8 ORF 8a X3 ORF 10 N/R 27,779-27,898 39 120 +2
mRNA 8 ORF 8b N/R ORF 11 X5 27,864-28,118 84 255 +3
mRNA 9 N protein N protein N protein N protein 28,120-29,388 422 1,269 +1
mRNA 9 ORF 9b N/R ORF 13 N/R 28,130-28,426 98 297 +2
SARS-CoV protein products
5′ and 3′ UTR
The 5′ UTR of the SARS-CoV genome was charac-
terized by 5′ Rapid Ampliﬁcation of cDNA Ends (5′
RACE; ref. 14 ) and Northern blot assay (13, 16,
22 ). These procedures elucidated the leader sequence
and the transcription regulatory sequence (TRS). The
leader sequence found in the viral sg mRNA tran-
scripts is at least 72 nucleotides long. Through the
alignment of the leader sequence at the 5′ end of the
eight sg mRNAs, there is a minimal consensus TRS,
namely, 5′-ACGAAC-3′, which participates in the dis-
continuous synthesis of sg mRNAs as a signaling se-
quence. The degree of sequence variance ﬂanking the
TRS showed no clear relationship with the abundance
of the sg mRNAs (22 ). A highly conserved s2m motif
with 32 nucleotides was also identiﬁed in the 3′ region
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of the genome, which had also been described in avian
infectious bronchitis virus (AIBV; ref. 12 -14 ).
Replicase Gene
The replicase gene of the SARS-CoV encodes for
at least two proteins as a consequence of the pro-
teolytic processing of the large polyprotein (ORF
1a and 1b; ref. 16 ). The translation of seg-
ment 1b of such polyprotein is interrupted by the
−1 ribosomal frame shifting by a putative “slip-
pery” sequence and a putative pseudoknot struc-
ture (16 ). Two functional domains—papain-like cys-
teine proteinase (PL2PRO) and 3C-like cysteine pro-
teinase (3CLPRO), were identiﬁed experimentally and
were responsible for the proteolytic processing of the
polyprotein into 16 subunits (16 , 22 , 23 ). A 375-a.a.
SARS-CoV unique domain was identiﬁed upstream
of the PL2PRO domain, which is unparalleled in any
other known coronaviruses (16 ). In addition, seven
more putative regions encoding RNA processing en-
zymes were identiﬁed, namely, RNA-dependent RNA
polymerase (RDRP), RNA helicase (HEL) poly (U)-
speciﬁc endoribonuclease (XendoU), 30-to-50 exonu-
clease (ExoN), S-adenosylmethionine-dependent ri-
bose 20-O-methyltransferase (20-O-MT), adenosine
diphosphate-ribose 100-phosphatase (ADRP), and a
cyclic phosphodiesterase (CPD; ref. 16 ).
The translation of two polyproteins from ORF 1a
and 1b starts the genome expression. The two pro-
teinases, PCL2PRO and 3CLPRO, are then coupled
with the proteolytic processing of the two polypro-
teins into 16 units. PCL2PRO is responsible for the
N-proximal cleavage and 3CLPRO is responsible for
the C-proximal cleavage. The helicase is then re-
leased. ATPase activity and DNA duplex-unwinding
activity were demonstrated by puriﬁed helicase, indi-
cating that the protein has RNA polymerase activity
(16 , 24 ).
S Gene
Together with the M protein, the spike protein is be-
lieved to be incorporated into the viral envelope be-
fore the mature virion is released (17 ). Initial anal-
ysis of the 1255-a.a. peplomer protein of the virus
reveals the possible existence of a signal peptide that
would likely be cleaved between residues 13 and 14
(12 ). The whole structure is predicted to contain a
receptor-binding unit (S1) in the N-terminus (14 , 25 -
27 ) and a transmembrane unit (S2) in the C-terminus
(13 , 14 , 25 , 27 ). Molecular modeling of the S1 and
S2 subunits of the spike glycoprotein (26 , 28 ) sug-
gested that the former unit is consisted of mainly
anti-parallel β-sheets with dispersed α and β regions,
in addition to the three domains identiﬁed in the S2
unit. The conﬁdence level of the predicted molecular
models was strengthened by the good correlation be-
tween predicted accessibility and hydropathy proﬁles
and by the correct locations of the N/O-glycosylation
sites and most of the disulﬁde bridges. Whether the
experimentally determined N-glycosylated sites from
puriﬁed spike protein treated by tryptic digest to-
gether with PNGase followed by time-of-ﬂight (TOF)
mass spectrometry (29 ) are correctly located in the
proposed model remains to be clariﬁed. In the as-
pect of biological activities, receptors for the binding
of the SARS-CoV remain mysterious, as comparative
genomics did not point out any signiﬁcant similarity
with the S1 domain of other human coronaviruses,
implying that these viruses are using diﬀerent recep-
tors for cell entry (12 ). Subsequently, angiotensin-
converting enzyme 2 (ACE2) was demonstrated to
be a functional receptor for the SARS-CoV in vitro.
Synctia was observed in cell culture expressing ACE2
and the SARS-CoV S1 domain, which could be in-
hibited by anti-ACE2 antibody (30 ). Fine mapping
on the N-terminal unit of the spike protein indicates
that the receptor-binding domain is probably located
between the residues 303 and 537 (31 ).
ORF 3a
The sequence of the gene product from ORF 3a shows
no homology to any known proteins (12 , 14 ). Sig-
nal peptide or a cleaved site is likely to be present
in the protein except three predicted transmembrane
domains (12 ). The exact function of the protein is
yet to be determined, though the C-terminal of the
protein may be involved in ATP-binding properties
(12 ).
E Gene
The envelope protein of the SARS-CoV is thought to
be the component of the virus envelope. Topology
prediction suggested that the E protein is a type II
membrane protein with the C-terminus hydrophilic
domain exposed on the virion surface. Comparative
protein sequence analysis suggested the SARS-CoV E
protein resembles the protein connected with MHV
(12 , 32 , 33 ).
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M Gene
The matrix glycoprotein is not likely to be cleaved
(12 ) and contains three putative transmembrane do-
mains (12 -14 ). Its hydrophilic domain is believed to
interact with the nucleocapsid protein and is located
inside the virus particle (12 ). Linear epitope mapping
of the M protein using synthetic peptides revealed
that amino acid residues 2,137-2,158 interacted with
SARS patient sera by ELISA assay, implying the po-
tential capability of the M protein to induce immune
response (34 , 35 ).
ORF 7a and 8a
Like ORF 3a, sequence homology search yielded no
signiﬁcant result for any existing proteins, but the ex-
istence of a cleavage site (between residues 15 and 16)
and a transmembrane helix were predicted. For ORF
7a, it is a putative type I membrane protein (12 ).
N gene
The N gene sequence showed high homology with the
nucleocapsid protein of other coronaviruses. A puta-
tive short lysine-rich nuclear localization signal (KTF-
PPTEPKKDKKKKTDEAQ) was identiﬁed (12 ). A
potential and well-conserved RNA interaction domain
was also identiﬁed at the middle region of the gene,
in which its basic nature may assist its role (12 , 14 ).
The N protein was reported to activate the AP-1 sig-
nal transduction pathway, indicating that the protein
may play a role in the regulation of the host cell cycle
(36 ). Apart from the possible role in pathogenicity, N
gene was also believed to be the most abundant anti-
gen in the host during the course of infection, mak-
ing it an excellent candidate for diagnostic purposes.
The linear epitopes of the protein have been mapped
(35 , 37 , 38 ), and the possibility of using these anti-
genic peptides or recombinant proteins in the diagno-
sis was discussed.
Phylogenetic analysis of the SARS-CoV
Protein sequence based on individual ORFs
The phylogenetic relationship by the comparison of
the deduced amino acid sequences of the replicase
gene and four structural genes (S, E, M, N) with other
coronaviruses was described (12 -14 ). The conclusions
drawn by the diﬀerent research groups were similar,
with the observation that SARS-CoV itself forms a
distinct cluster—the fourth group of Coronaviridae, a
notion supported by the high bootstrap values (above
90%). As a result, it has been concluded that the
SARS-CoV is phylogenetically equidistant from all
other known coronaviruses. Moreover, no detectable
recombination event was concluded in the similarity
plot on the whole genome alignment with other coro-
naviruses (14 ). The above ﬁndings suggest that the
SARS-CoV is neither a mutant nor a recombinant of
existing coronaviruses, and that the possibility of such
a virus emerging as a product of genetic engineering
can be excluded, as it is unlikely to generate an in-
fectious coronavirus with 50% of its genome diﬀerent
from the existing coronaviruses (9 ).
Protein sequence based on functional domain
of the replicase gene
Snijder et al (22 ) conducted an extensive phyloge-
netic analysis concerning the replicase gene of the
SARS-CoV by using torovirus as an outgroup. These
authors criticized the phylogram construction based
on diﬀerent SARS-CoV proteins as unconvincing, and
suggested the possibility that the SARS-CoV can be
clustered into an existing group. As the structural
and other accessory genes can either be gained or lost
throughout the evolutionary process and in view of
their low level of conservation, the author decided
to target the replicase gene to perform the phyloge-
netic analysis. For this reason, the phylogenetic re-
lationship was reconstructed through a rooted tree.
The construction of the phylogram was done with the
fused replicase gene with manual adjustment and ex-
clusion of poorly conserved region. The resulting tree
reveals that the gene was mostly related to group
2 coronaviruses and was assigned as a subgroup 2b.
The author further pointed out that the SARS-CoV
contains homologues of domains that are unique for
group 2 coronaviruses, in the region of nsp1 and nsp3
(PL2PRO), in addition to the diﬀerences in the se-
quence and arrangements of the 3′-located ORFs, and
the lack of antigenic cross-reactivity do not contradict
their conclusion, as such a phenomenon was also ob-
served in group 1 coronaviruses.
Using Bayesian phylogenic inference approach, a
recombination break point within the SARS-CoV
RDRP was identiﬁed at protein sequence level (39 ).
Phylogenetic analysis on the 5′ end of the domain
indicated that it might originate from the common
ancestor of all existing coronaviruses, while the same
analysis on the 3′ end gave another tree topology that
250 Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003
Chow et al.
suggests a sister relationship with group 3 avian coro-
naviruses. These results suggested that a recombina-
tion event occurred between the common ancestor of
the SARS-CoV and that of other coronaviruses, or al-
ternatively that the 5′ fragment of the SARS-CoV di-
verged before the one between or within other known
coronaviruses and the 3′ fragment diverged more re-
cently (39 ).
Genome organization
Based on the antigenic cross reactivity and genome
characteristics, existing coronaviruses are generally
classiﬁed into three subgroups (40 ). All coronaviruses
share a very similar organization in their functional
and structural genes, but the arrangement of the
so-called non-essential genes is remarkably diﬀerent
among the subgroups. Group 1 coronaviruses are
mainly characterized by the presence of ORFs follow-
ing the N gene. Group 2 coronaviruses have two addi-
tional ORFs, non-structural protein 2 (ns2) and HE
gene, located between ORF 1b and the S gene. Only
group 3 species have ORFs located between the M
and N gene, and a conserved stem-loop motif s2m at
their 3′ UTR (Figure 1). Accessory ORFs are found
between the S and E genes in all of the subgroups.
However, these accessory ORFs within the S-E inter-
genic region do not seem to be homologous between
the subgroups, though they are conserved within sub-
groups. The rate of evolution of these accessory genes
is obviously higher than that of the essential genes,
which provides an alternative to access the phylogeny
of the coronavirus family.
Fig. 1 Comparison of accessory genes among all known coronaviruses. The open boxes represent essential ORFs (not
drawn to scale) while the shaded boxes represent accessory ORFs/motifs. Homologous ORFs are shaded with the same
pattern. The names of the group-speciﬁc accessory ORFs were uniﬁed and denoted on the top of the corresponding
subgroup ORFs. The X (black cross) represents the absence of ORFs within the region. Genome organization and
accessory ORFs of these CoVs were conﬁrmed except for the n2s of PHEV. All the accessory genes are group-speciﬁc
and highly diverged within subgroups, particular within the S−E intergenic region. SARS-CoV has a very similar
genome structure with group 3 CoVs, with two ORFs located between M and N gene, and a conserved stem-loop motif
s2m at their 3′ UTR. Although the ORF 5a/5b of group 3 CoVs and ORF 5/6 of SARS-CoV are in homologous location,
they do not have any signiﬁcant sequence homology. FECV: feline enteric coronavirus (41 -45 ); FIPV: feline infectious
peritonitis virus (41 -45 ); CCV: canine coronavirus (43 , 46 ); TGEV: transmissible gastroenteritis virus (41 , 47 , 48 );
PRCV: porcine respiratory coronavirus (41 , 47 , 48 ); PEDV: porcine epidemic diarrhea virus (49 , 50 ); HCV 229E:
human coronavirus 229E (49 , 51 ); MHV: murine hepatitis virus (52 , 53 ); RCV: rat coronavirus (54 ); BCV: bovine
coronavirus (55 ); PHEV: porcine hemagglutinating encephalomyelitis virus (56 ); HCV OC43: human coronavirus
OC43 (57 , 58 ); TCV: turkey coronavirus (59 -61 ); IBV: infectious bronchitis virus (62 -64 ).
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Based on the conﬁrmed ORFs of the SARS-CoV
described above, a comparison of all homologous ac-
cessory and essential ORFs of known coronaviruses
with the novel SARS-CoV is shown in Figure 1. From
the results, it does not seem that the coding regions
are a consequence of a newly occurring recombina-
tion event between any of the existing known coro-
naviruses, similar to the conclusion made by Holmes
(9 ). Interestingly, the SARS-CoV genome has a very
similar organization to that of group 3 avian coron-
aviruses (IBV and TCV), with the presence of three
ORFs within the M-N intergenic region, two ORFs
spanning between the S and E genes (65 ), and a
stem-loop motif s2m in 3′ UTR. The presence of s2m
and the ﬁnding that the 3′ fragment of SARS-CoV
RDRP clustered into group 3 in the phylogenetic anal-
ysis (39 ) suggest that the avian coronaviruses and
the SARS-CoV might share a common ancestor which
gained the s2m from a single RNA horizontal trans-
fer event from a non-related virus family, as the as-
troviruses did (39 , 66 ). Another possibility, that a
common coronavirus ancestor had once gained the
motif but subsequently lost it, except the group 3
and SARS-CoV, cannot of course be excluded. Pair-
wise sequence homology search among the accessory
ORFs at the S-E intergenic region of the SARS-CoV
and all other coronaviruses shows no signiﬁcant se-
quence homology (12 -14 ) but they are homologous
within subgroups. The ORF 5a/5b of group 3 coro-
naviruses and ORFs 6-8 of the SARS-CoV are in a
homologous location, but they do not have any sig-
niﬁcant sequence homology. The above results im-
ply that, although the SARS-CoV and group 3 coron-
aviruses have a very similar genome organization, they
might have acquired these accessory genes from sev-
eral RNA recombination events with diﬀerent hosts
or viral sources. It is observed that the accessory
ORFs are group-speciﬁc but are usually truncated to
a diﬀerent extent within a subgroup (Figure 1). An-
other interesting observation is the genetic diversity
at the S-E intergenic region. Usually two or three
group-speciﬁc ORFs are found within this region of
each subgroup, but only one conﬁrmed ORF (ORF
3) is found in this region of the SARS-CoV genome
(12 -14 , 16 , 22 ). The diversity (mainly due to trunca-
tion and deletion) of these S-E intergenic ORFs within
the subgroups is higher than that of other accessory
ORFs. Their sequence divergence implies their com-
mon ancestors might have acquired these ORFs by
RNA recombination, which is a common phenomenon
in large RNA viruses (67 , 68 ), rather than evolved
from mutations of a single ancestral RNA sequence
segment (9 ). Typical examples are the acquirement
of the HE gene from Inﬂuenza C (69 ) and recombi-
nation events with Berne virus at the HE-ns2 region
(52 ).
Based on the recombination and truncation events
occurring within these intergenic regions, the phyloge-
netic relationship between the SARS-CoV and other
group 3 coronaviruses has been reconstructed (Fig-
ure 2). At least four subgroup common ancestors (♦
in Figure 2) have acquired their S-E intergenic ORFs
and other group-speciﬁc ORFs from several indepen-
dent RNA recombination events. Moreover, there is a
tendency of deletions or truncations of these ORFs
when crossing the species barriers within the sub-
groups, e.g. ORF 4a/b in group 2 (54 -58 ); ORF 3a/b
and ORF 7a/b in group 1 (41 , 42 , 47 , 48 , 50 , 70 -72 ).
The deletions of these redundant accessory ORFs are
likely to be the result rather than the cause of crossing
the host barriers, as coronavirus host range speciﬁcity
and tropism have been demonstrated, at least in four
studies (7 , 73 -75 ), as determined by the receptor-
binding domain of the spike glycoprotein.
Recombination within certain types of viruses is a
common phenomenon in various virus families (67 ),
particularly for large RNA viruses, as a means of shed-
ding the deleterious eﬀects of the errors accumulated
during its genome replication (68 ). Recombination
events within the coronavirus family (70 , 76 , 77 ) or
with other non-related virus families (52 , 66 , 69 ) have
been reported. Apparently, the diversity of the redun-
dant accessory genes has been accompanied by exten-
sive genome rearrangement by heterogeneous or ho-
mogenous RNA recombination events, providing use-
ful information for the taxonomy of the coronaviruses.
From this point of view, the SARS-CoV is deﬁnitely
a new and unique member of the coronavirus fam-
ily. The divergence of these redundant ORFs between
the SARS-CoV and other known coronaviruses sug-
gests that the SARS-CoV might have been circulating
in other animal hosts long before its emergence, and
somehow crossed into a human host several months
ago either by a sudden bottleneck mutation event or
a RNA recombination event with unknown sources.
Animal reservoir
It has been demonstrated that the SARS-CoV pos-
sesses the ability to infect macaques, which display
symptoms similar to the clinical signs of SARS pa-
tients (78 ), and to replicate in cats and ferrets (79 ).
252 Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003
Chow et al.
Fig. 2 Phylogenetic relationship of all known coronaviruses based on the putative RNA recombination events occurred
at the accessory ORFs. There are at least four subgroup common ancestors (♦ no.1-4) have acquired their redundant
accessory ORFs from several independent RNA recombination events. Group 3 CoVs and SARS-CoV may have a
common ancestor (♦ no.0) which gained s2m from a single RNA horizontal transfer event from a non-related family
of astroviruses (see text). There is a tendency of deletions or truncations of these accessory ORFs when crossing the
species barriers within the subgroups. The abbreviations of the viral species are shown in the legend of Figure 1.
Together with the evidence implied by the phyloge-
netic studies, it is tempting to identify the possible
animal reservoir of the coronavirus. Recent studies of
domestic and wild animals in Guangdong, where the
SARS epidemic was ﬁrst reported, identiﬁed the exis-
tence of the SARS-CoV from several animals found in
the livestock market, including Himalayan palm civets
(Paguma larvata) and raccoon dogs (Nyctereutes pro-
cyonoides ; ref. 80 ), in spite of the failure of another
group to identify any SARS-CoV after the screening
of more than 60 animal species (81 ). The genome
sequences of the coronaviruses isolated from these
animals are almost identical (99.8%) to that of the
SARS-CoV, revealing the extremely close phyloge-
netic relationship between them. Another major ﬁnd-
ing from the sequence analysis highlighted a 29-bp
deletion upstream the N gene, which was noted only
in one Guangdong isolate available from the Gen-
Bank (GD01, accession number 278489). Such dele-
tion leads to the fusion of the two ORFs identiﬁed in
mRNA 8 into one ORF. Yet its biological signiﬁcance
remains to be elucidated (8 ). Comparison of the S
gene nucleotide sequence of the animal and human
SARS-CoV indicated 11 consistent nucleotide signa-
ture mutations that appeared to distinguish them.
The phylogenetic analysis of the S gene sequence be-
tween human and animal SARS-CoV likely ruled out
the possibility that it is a consequence of human to an-
imal transmission, implying the infected animals may
acquired the virus from a true animal source that has
yet to be identiﬁed (80 ). This was also supported by
the host-association analysis of coronaviruses based
on the nucleocapsid gene (39 ), which pinpointed that
host-shifts had played an important role in the evo-
lution of the virus and the host. The occurrence
of avian-mammal host-shift supports the hypothesis
that the SARS-CoV emerged from an unknown ani-
mal coronavirus.
Reverse genetics system
The reverse genetics system, a very useful tool in
studying function of viral proteins and its mutations,
was ﬁrstly described by Master’s group (82 ) for MHV
in Coronaviridae. In less than six months since the
ﬁrst identiﬁcation of the SARS-CoV (2 ), Yount et al
(83 ) developed the reverse genetic systems for this
coronavirus using the full-length cDNA clone of Ur-
bani strain, by combining six component clones span-
ning through the entire genome. Following in vitro
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transcription and the transfection of the resulting
RNA transcripts, a rescued recombinant virus was
found to be capable of replication in the same way
as the wild type. Expected marker mutations intro-
duced were also identiﬁed. The success of the exper-
iment oﬀers hope for the development of attenuated
strains of live vaccine against the SARS-CoV (9 ).
SARS and human leukocyte antigen
(HLA) system
There is considerable scientiﬁc interest in the identi-
ﬁcation of the genetic agents responsible for the un-
usual susceptibility of the SARS-CoV in some eth-
nic groups. A molecular survey of the HLA sys-
tem, a common method adopted to identify au-
toimmune disorders and emerging infectious diseases,
was conducted in Taiwan during the SARS epi-
demic (84 ). Using PCR ampliﬁcation plus sequence-
speciﬁc oligonucleotide probing (PCR-SSOP), re-
searchers identiﬁed the HLA genotype of SARS pa-
tients. Healthy, unrelated Taiwanese were used as
controls, and the HLA genotype of SARS patients was
compared with probable cases and with high-risk, un-
infected health care workers. The results indicated
that a higher frequency of HLA-B*4601 allele was
found in severe SARS cases, which may explain the
severity of SARS in these patients. Such genotype,
as stated in the report, is common in Southern Han
Chinese, Singaporeans and Vietnamese, but not in
indigenous Taiwanese. There was no reported SARS
case within the latter ethnic group. Such ﬁndings may
explain the unusual SARS epidemic in South Asia.
Diagnosis of the SARS-CoV
Work on developing a laboratory diagnosis of the
SARS-CoV began immediately after the SARS out-
break, although an ideal diagnostic system is still be-
ing sought. Numerous protocols have been developed
for the diagnosis of infectious viral diseases. Most of
these protocols are PCR-based, and the remainder de-
pends on measurable immune response. Several fac-
tors aﬀect the choice of proper diagnosis techniques,
including time, the availability of equipment and ex-
pertise, the biological nature of the available samples,
and the requirement of data output format (Table 2;
ref. 10 ). The presence of the virus can be detected
by molecular testing such as PCR and virus isola-
tion. Measurable immune responses basically rely on
SARS-CoV speciﬁc antibodies by enzyme-linked im-
munosorbent assay (ELISA).
Table 2 Summary of Properties of Diﬀerent Diagnostic Methods
Features/Methods RT-PCR Virus isolation ELISA IFA Microarray
Speciﬁcity High High Relatively lower Relatively lower Relatively lower
Sensitivity Not very high Low High High Not very high
Valid duration of +ve result# d1−d10 d1−d10 d21−d31 d1−d31 d1−d10
Valid duration of −ve result# N/A N/A d21−d31 d21−d31 N/A
Convenience* Not very high Moderate High Not very high Low
Speed Relatively lower Slow High High High
# Result is deﬁned to be valid after the onset of fever where d=day. * Convenience means the requirement of expensive
equipment and skilled labor.
Molecular assays
Advances have been made in molecular diagnos-
tic techniques in recent years, and such rapid and
sensitive methods allow eﬃcient monitoring of in-
fectious viral diseases. For SARS, the ﬁrst ge-
netic fragment of the virus was generated by re-
verse transcriptase-polymerase chain reaction (RT-
PCR; ref. 2 ). Two RT-PCR protocols were then
developed by two WHO SARS network laboratories
(http://www.who.int/csr/sars/primers/en). The sen-
sitivities of the assay were demonstrated to be at
least 50%, with the highest percentage found in throat
swab specimens (85 ). No false positive was found in
these assays.
The ﬁrst rapid real-time assay was developed
based on the most conserved region of the ORF1b
gene sequence (86 , 87 ). A person will be conﬁrmed to
be infected by the SARS-CoV if viral RNA is detected
by either the two PCR assays, two aliquots of speci-
men, or two sets of primers (http://www.cdc.gov/nci
dod/sars/specimen collection sars2.htm). The sec-
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ond generation of this test protocol can detect the
existence of the virus within 10 days after the onset of
fever (87–89) and provides 80% sensitivity and 100%
speciﬁcity in the testing of 50 NPA samples collected
from SARS patients within three days after the onset
of the disease (87 ). To further increase the sensitivity,
one-step real-time RT-PCR has been recently devel-
oped (89 ). Speciﬁcity of the PCR can be enhanced by
coupling it with the use of an additional ampliﬁcation
target using the virus N gene fragment (89 ), which is
theoretically the most abundant subgenomic mRNA
produced during transcription (13 ). The technique
provides information on viral load during anti-viral
treatments in real time, so that the eﬃcacy of the
therapy can be evaluated (10 ). However, although
the PCR assays are powerful, their performance is
also technically demanding and labor intensive (10 ).
The development of microarray technology for vi-
ral discovery was ﬁrstly described by Wang et al in
2002 (90 ). The capability of the rapid high through-
out screening of unknown viral pathogen gives it great
potential to be used as a diagnostic tool. In the identi-
ﬁcation of the SARS-CoV, Wang et al (11 ) employed
the use of an improved microarray platform, which
comprised conserved 70mers from each of the 1,000
viruses, to characterize the coronavirus genome. Four
hybridizing oligonucleotides from Astroviridae which
share the s2m motif and three from Coronaviridae
sharing conserved ORF1ab fragment were ﬁrstly rec-
ognized in the experiment. The sequence recovered
from the surface of the microarray further conﬁrmed
that it is a member of the coronavirus family. The
identity of the SARS-CoV was conﬁrmed within 24
hours, and this feat was followed by the partial se-
quencing of the novel virus a few days later. Such
technique demonstrated a rapid and accurate means
of unknown virus characterization through genetic
data.
Virus isolation
Virus isolation by cell culture is used extensively as
a traditional technique in virology. Coronavirus pre-
senting in the clinical specimens of SARS patients was
detected by inoculating the clinical specimens in cell
cultures to allow the infection and the subsequent iso-
lation of the virus. Fetal rhesus kidney (FRhK-4; ref.
2 ) and vero cells (3 ) were found to be susceptible to
SARS-CoV infection. After the isolation procedure,
the pathogen was identiﬁed as the SARS-CoV by fur-
ther tests, such as electron microscopy, RT-PCR, or
immunoﬂuorescent viral antigen detection. Virus iso-
lation is the only means to detect the existence of live
virus from the tissue. The methodology is generally
employed only for a preliminary identiﬁcation of an
unknown pathogen, as the procedure requires skillful
technicians and is time consuming. The requirement
of infectious viruses and that the duration of live virus
existence varies add on further problems for conduct-




The N protein is usually chosen as the antigen for anti-
coronavirus antibody detection assay (91 , 92 ) as it is
believed to be a predominant antigen of the SARS-
CoV (35 , 36 ). It is also the only viral protein recog-
nized by acute and early convalescent sera from pa-
tients recovering from SARS (29 ). In addition to the
N protein, the S protein in the SARS-CoV was also
reported as an antigen eliciting antibodies in human
body (29 ), but at a much lower titer than that of the
N protein (35 , 36 ).
The assay based on the presence of SARS-CoV
antibodies is suggested to be valid only for speci-
mens obtained more than three weeks after the on-
set of fever (88 , 89 ), although some patients have
detectable SARS-CoV antibodies within 14 days of
the onset of illness. Nevertheless, the negative re-
sult, i.e. absence of SARS-CoV antibodies, within
the ﬁrst three weeks cannot conclude that the pa-
tient is free of the virus, though the ELISA method
was still deﬁned as a good standard for rapid diag-
nosis of SARS (85 ). Seroconversion from negative
to positive or a four-fold rise in antibody titer from




The epidemiology of SARS has been extensively inves-
tigated since the outbreak of SARS in November 2002
in Guangdong (1 ). This traditional method was used
to access the epidemiology of SARS initially. Molec-
ular epidemiology can be used to trace the disease
transmission by using phylogenetic analysis of viral
nucleotide sequence, which can quickly identify and
aid in monitoring the transmission (93 ).
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In coronavirus, variations in the spike protein can
drastically aﬀect viral entry, pathogenesis (94 ), anti-
viral immune response (29 ), virulence (95 ), cellular
(6 ), or even species tropism (7 ). The S gene has been
used as a target for genotyping most coronaviruses,
like human coronaviruses (96 ) and IBV (97 ). Study
of the N-terminal region of the SARS-CoV spike pro-
tein produced similar conclusions by conventional epi-
demiology methods (98 ). The investigation included
the collection S1 gene sequences from SARS patients
in Hong Kong and Guangdong during February-April
2003 mainly by direct sequencing of RT-PCR prod-
ucts derived from clinical specimens, and compared
it phylogenetically to additional 27 other sequences
available from GenBank. The majority of the Hong
Kong viruses, including those from a large outbreak
in a high-rise apartment block, Amoy Garden, clus-
tered to a single index case that came from Guang-
dong to Hong Kong in late February (Figure 3). Most
of the viruses derived from Hong Kong patients be-
long to the same lineage with viruses derived from the
Hong Kong index case. Outbreaks in Canada, Sin-
gapore, Taiwan and Vietnam were also derived from
the SARS-CoV of the same initial virus lineage as
judged from the same phylogenetic analysis. A num-
ber of viruses derived from the early patients were
excluded from the major lineage and formed distinct
cluster, implying multiple introductions of the virus
have occurred, although these viruses did not caused
large-scale outbreaks. Viral sequences identiﬁed in
Guangdong and Beijing are genetically more diverse
(1 , 98 ), implying that the SARS-CoV has been cir-
culating there for a while before the introduction to
Hong Kong. The Hong Kong index case that initiated
the ﬁrst super-spreading incident to aﬀect 12 other
patients might be simply a matter of chance or the
viruses found in that patient were contagious to initi-
ate super-spreading events, but these still need further
investigations. Apart from ﬁndings that indicate the
possible transmission routes, transitional isolates that
possess both the characteristics of two lineages were
also identiﬁed. Ruan et al (99 ) and Tsui et al (100 )
performed similar analysis based on the comparison of
full genome sequences of diﬀerent SARS-CoV isolates.
They independently identiﬁed some of the variations,
as Guan et al (98 ) did. Chiu et al (101 ) have recently
identiﬁed the nucleotide substitution in the S gene
that is unique to the Taiwan isolates and was linked
to the Hong Kong index case. Sequence comparison
of the Amoy Garden isolates revealed no signiﬁcant
variations within the S1 gene, or across the whole
genome, implying that other non-viral factors may
contribute to the abnormal transmission and clinical
presentation of SARS in this cluster of high-rise apart-
ments (98 , 102 ). In summary, the transmission route
of the SARS-CoV in diﬀerent countries and areas cor-
relates well with the traditional epidemiological ﬁnd-
ings, implying the successful application of molecular
epidemiological techniques in tracing the virus trans-
mission history.
Concerning viral evolution, Zeng et al (103 ) have
performed a linear regression analysis and tried to es-
timate the last appearance of the SARS-CoV common
ancestor. With such eﬀort, which has been success-
fully applied in timing of the ancestral sequence of
human immunodeﬁciency virus (HIV; ref. 104 ), the
ancestral sequence is believed to have appeared last in
late 2002. These preliminary ﬁndings provide impor-
tant information for tracing the origin of the SARS-
CoV and monitoring its spread.
Immunity, Vaccination and Anti-
viral Drug Design
Current knowledge on coronavirus immunity has
mainly been acquired from research on animal coro-
naviruses. Clinical observations have shown that hu-
moral and cell-mediated immune responses may be
both necessary against SARS-CoV infection (105 ). It
was reported that T cell (CD3+, CD4 and CD8+)
depletion was observed in early infection, but that
levels returned to normal as the disease was improved
(106 ). IgG antibody could be detected at the 7th
day after the onset of symptoms and kept at high
titer at least three months (107 ). Another report in-
dicated that the virus was still detectable in respira-
tory and stool specimens by RT-PCR diagnosis but
could not be cultured more than 40 days after pre-
sentation (108 ), implying that the antibody could be
stimulated rapidly and might restrict the virus infec-
tion. However it has also been reported in fowl and
feline coronaviral diseases that low-level antibody may
exacerbate diseases (109 ). It is therefore important
to conduct further investigations into the immune re-
sponse to SARS patients in the future so as to beneﬁt
the vaccine development and disease control.
Concerning the candidate target for vaccine de-
velopment, the S1 unit of the spike proteins has been
identiﬁed as the host protective antigen and used as
a vaccine candidate in other coronaviruses (110 ). An
extensive structural analysis of the corresponding pro-
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Fig. 3 Phylogenetic analysis of 169 SARS-CoV spike genes. Unrooted trees were constructed based on the optimal
alignment by neighbor-joining method using MEGA 2. Number at the nodes indicates boostrap values in percentage.
The branch length shows the genetic distance with reference to the horizontal scale bar. All sample names were hidden
for the convenience of display, except the index case isolate HKU-33 (gray) and subcluster transition isolates (dark).
The locations of these isolates on the tree were pinpointed by dots besides their names. The hypothetical common
ancestors of the subclusters were highlighted as described in the right bottom of the ﬁgure.
tein in SARS is thus desirable. With the identiﬁcation
of the SARS-CoV functional receptor (30 ) and the
mapping of the receptor-binding domain on the spike
protein (31 ), subunit vaccine targeting the receptor-
binding domain and the preparation of killed or at-
tenuated vaccine using ACE2 expression cell line may
be promising (30 ).
Antiviral drugs represent an alternative anti-
SARS strategy to vaccination. Inhibiting chemicals
targeting the SARS-CoV replication-related proteins
were considered as anti-SARS-CoV drug candidates,
e.g. inhibition the enzymatic activity of 3CLPRO.
An extensive structural analysis of 3CLPRO encoded
from nsp5 on ORF 1a was performed (28 , 111 ). The
3CLPRO structure showed a considerable degree of
conservation of the substrate-binding sites, with the
evidence that it could retain its proteolytic activ-
ity upon TGEV (transmissible gastroenteritis virus)
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main proteinase (111 ), though another group men-
tioned that the inactive property of the enzyme might
exist in vitro (112 ). From this result, these authors
suggested that the use of rhinovirus 3CPRO inhibitor
might be useful in anti-SARS therapy. Two months
later, a research group from the US conducted a study
on the interaction of two chemicals (KZ7088 and the
AVLQSGFR octapeptide) with 3CLPRO (113 ), fur-
ther highlighting the importance of the main pro-
teinase as a target for anti-viral drug design. Fan et al
(114 ) provided valuable additional information, and
concluded that only the dimeric form of the 3CLPRO
is active and that the proteinase-substrate interac-
tion can be speeded up if more beta-sheet-like struc-
ture is involved in the substrate. Recently the crys-
tal structure of 3CLPRO was reported by Yang et al
(115 ). The 3CLPRO crystal underwent conforma-
tional changes under diﬀerent pH conditions while
complexing with the speciﬁc inhibitor at the same
time. A serine-protease fold with a Cys-His at the
active site was recognized. On the other hand, the
modeling of the structure of 20-O-MT domain located
at nsp16 was proposed by von Grotthuss et al (116 )
using the 3D jury system with high reliability (3D jury
score >100). The conservation of the unique tetrad
residues K-D-K-E of the domain assigned a proposed
mRNA cap methylation function of this domain, sug-
gesting an alternative target for anti-viral drug design.
In addition to main proteases, blocking the virus en-
try should be considered as well. Structural analysis
of the S2 domain of the SARS-CoV S protein, which
plays a role in fusion of the virus with host cell, re-
vealed a conservation of sequence motifs with the well-
studied gp41 protein of HIV-1 and other viruses with
class I transmembrane domain (27 ). Such a structure
may be another target for drug design.
Conclusion
The collaborative eﬀorts of the global scientiﬁc com-
munity have provided invaluable insights into the
molecular biology of the SARS-CoV. The develop-
ment of a rapid and accurate method of diagnosis
based on the molecular ﬁndings has helped to identify
SARS patients at an early stage of the disease, thereby
providing valuable information for national authori-
ties to monitor the spread of the disease and take ef-
fective quarantine measures, and contributing to the
understanding of the clinical presentations of the syn-
drome. The elucidation of the molecular biology of
the SARS-CoV has provided a foundation for vaccine
design and narrowed down the targets for large-scale
high throughput drug screening program for anti-viral
therapy. These advances helped the global commu-
nity to contain the spread of SARS within four months
since its ﬁrst identiﬁcation. However, much remains
to be discovered about this novel coronavirus, and it
may yet pose a serious threat. Unlike other recently
identiﬁed viral diseases like Ebola andWest Nile virus,
it seems the transmission of SARS-CoV does not need
a visible vector for spreading, and that a tiny, invisi-
ble, respiratory droplet is suﬃcient to infect another
person (117 ). The nearly undetectable symptom pre-
sented by the recently conﬁrmed SARS case in Sin-
gapore suggests that the virus may continue to cir-
culate undetectably (65 ). The possibility that com-
mon domestic animals are also a virus reservoir for
SARS further complicates the struggle to contain and
ultimately eradicate this disease. In these aspects,
sensitive, accurate and rapid diagnosis plays an ex-
tremely important role in limiting the disease spread,
especially in the developing world and densely pop-
ulated countries. Luckily, the aggressive quarantine
measures imposed by the WHO proved to be eﬀec-
tive in containing the outbreak, and the experience
gained in the last SARS outbreak has prepared us to
face another outbreak with some conﬁdence. Never-
theless, nobody can predict exactly when an eﬀective
vaccine or anti-viral drug will be developed. All that
can be said is that, based on our growing knowledge
of the molecular epidemiology and evolution of the
virus, the successful development of countermeasures
to SARS is very possible.
Acknowledgements
We wish to thank speciﬁcally our colleagues at the
Department of Microbiology inviting us to join in the
SARS research eﬀort. We feel sad about all the life
loss caused by SARS and particularly the medical
staﬀs who were infected and died in taking care of
SARS patients.
References
1. Zhong, N.S., et al. 2003. Epidemiology and cause of
severe acute respiratory syndrome (SARS) in Guang-
dong, People’s Republic of China, in February. Lancet
362: 1353-1358.
258 Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003
Chow et al.
2. Peiris, J.S., et al. 2003. Coronavirus as a possible
cause of severe acute respiratory syndrome. Lancet
361: 1319-1325.
3. Drosten, C., et al. 2003. Identiﬁcation of a novel
coronavirus in patients with severe acute respiratory
syndrome. N. Engl. J. Med. 348: 1967-1976.
4. Ksiazek, T.G., et al. 2003. A novel coronavirus as-
sociated with severe acute respiratory syndrome. N.
Engl. J. Med. 348: 1953-1956.
5. Peiris, J.S. 2003. Severe acute respiratory syndrome
(SARS). J. Clin. Virol. 28: 245-247.
6. Casais, R., et al. 2003. Recombinant avian infectious
bronchitis virus expressing a heterologous spike gene
demonstrates that the spike protein is a determinant
of cell tropism. J. Virol. 77: 9084-9089.
7. Haijema, B.J., et al. 2003. Switching species tropism:
an eﬀective way to manipulate the feline coronavirus
genome. J. Virol. 77: 4528-4538.
8. Sstadler, K., et al. 2003. SARS—Beginning to under-
stand a new virus. Annu. Rev. Microbiol. 1: 209-218.
9. Holmes, K.V. 2003. SARS coronavirus: a new chal-
lenge for prevention and therapy. J. Clin. Invest. 111:
1605-1609.
10. Ellis, J.S. and Zambon, M.C. 2002. Molecular diagno-
sis of inﬂuenza. Rev. Med. Virol. 12: 375-389.
11. Wang, D., et al. 2003. Viral discovery and sequence
recovery using DNA microarrays. PLoS Biol. 1: E2.
12. Marra, M.A., et al. 2003. The genome sequence of
the SARS-associated coronavirus. Science 300: 1399-
1404.
13. Rota, P.A., et al. 2003. Characterization of a novel
coronavirus associated with severe acute respiratory
syndrome. Science 300: 1394-1399.
14. Zeng, F.Y., et al. 2003. The complete genome se-
quence of severe acute respiratory syndrome coron-
avirus (SARS-CoV) strain HKU-39498 (HK-39). Exp.
Biol. Med. 228: 866-873.
15. Leung, F.C. 2003. Hong Kong SARS sequence. Sci-
ence 301: 309-310.
16. Thiel, V., et al. 2003. Mechanisms and enzymes in-
volved in SARS coronavirus genome expression. J.
Gen. Virol. 84: 2305-2315.
17. Lai, M.M. and Cavanagh, D. 1997. The molecular bi-
ology of coronaviruses. Adv. Virus Res. 48: 1-100.
18. Lai, M.M. 1990. Coronavirus: organization replication
and expression of the genome. Annu. Rev. Microbiol.
44: 303-333.
19. Lai, M.M., et al. 1994. Coronavirus: how a large
RNA viral genome is replicated and transcribed. In-
fect. Agents Dis. 3: 98-105.
20. Lai, M.M., et al. 1987. Coronavirus: a jumping RNA
transcription. Cold Spring Harb. Symp. Quant. Biol.
52: 359-365.
21. Lai, M.M. and Holmes K.V. 2001. Coronaviridae and
their replication. In Fields’ Virology (eds. Knipe, D.,
et al.), Lippincott Williams & Wilkins, Philadelphia,
USA.
22. Snijder, E.J., et al. 2003. Unique and conserved fea-
tures of genome and proteome of SARS-coronavirus,
an early split-oﬀ from the coronavirus group 2 lineage.
J. Mol. Biol. 331: 991-1004.
23. Gao, F., et al. 2003. Prediction of proteinase cleavage
sites in polyproteins of coronaviruses and its applica-
tions in analyzing SARS-CoV genomes. FEBS Lett.
553: 451-456.
24. Tanner, J.A., et al. 2003. The severe acute respira-
tory syndrome (SARS) coronavirus NTPase/helicase
belongs to a distinct class of 5′ to 3′ viral helicases. J.
Biol. Chem. 278: 39578-39582.
25. Li, J.X., et al. 2003. The structural characterization
and antigenicity of the S protein of SARS-CoV. Geno.
Prot. Bioinfo. 1: 108-117.
26. Spiga, O., et al. 2003. Molecular modelling of S1 and
S2 subunits of SARS coronavirus spike glycoprotein.
Biochem. Biophys. Res. Commun. 310: 78-83.
27. Bosch, B.J., et al. 2003. The coronavirus spike pro-
tein is a class I virus fusion protein: structural and
functional characterization of the fusion core complex.
J. Virol. 77: 8801-8811.
28. Yan, L., et al. 2003. Assessment of putative protein
targets derived from the SARS genome. FEBS Lett.
554: 257-263.
29. Krokhin, O., et al. 2003. Mass spectrometric charac-
terization of proteins from the SARS virus. Mol. Cell
Proteomics 2: 346-356.
30. Li, W., et al. 2003. Angiotensin-converting enzyme
2 is a functional receptor for the SARS coronavirus.
Nature 426: 450-454.
31. Xiao, X., et al. 2003. The SARS-CoV S glycoprotein:
expression and functional characterization. Biochem.
Biophys. Res. Commun. 312: 1159-1164.
32. Shen, X., et al. 2003. Small envelope protein E of
SARS: cloning, expression, puriﬁcation, CD determi-
nation, and bioinformatics analysis. Acta Pharmacol.
Sin. 24: 505-511.
33. Wu, Q.F., et al. 2003. The E protein is a multifunc-
tional membrane protein of SARS-CoV. Geno. Prot.
Bioinfo. 1: 131-144.
34. Hu, Y.W., et al. 2003. The M protein of SARS-CoV:
basic structural and immunological properties. Geno.
Prot. Bioinfo. 1: 118-130.
35. Wang, J.Q., et al. 2003. Assessment of immunoreac-
tive synthetic peptides from the structural proteins of
severe acute respiratory syndrome coronavirus. Clin.
Chem. 49: 1989-1996.
36. He, R., et al. 2003. Activation of AP-1 signal trans-
duction pathway by SARS coronavirus nucleocapsid
protein. Biochem. Biophys. Res. Commun. 311:
870-876.
Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003 259
Molecular Advances in SARS-CoV
37. Wang, J.Q., et al. 2003. The structure analysis and
antigenicity study of the N protein of SARS-CoV.
Geno. Prot. Bioinfo. 1: 145-156.
38. Lin, Y., et al. 2003. Identiﬁcation of an epitope of
SARS-coronavirus nucleocapsid protein. Cell Res. 13:
141-145.
39. Rest, J.S. and Mindell, D.P. 2003. SARS-associated
coronavirus has a recombinant polymerase and coron-
aviruses have a history of host-shifting. Infect. Genet.
Evol. 3: 219-225.
40. Lai, M.M. and Holmes, K.V. 2001. Coronaviruses. In
Fields’ Virology (eds. Knipe, D., et al.), pp. 1163-
1185. Lippincott Williams & Wilkins, Philadelphia,
USA.
41. de Groot, R.J., et al. 1988. Sequence analysis of the
3′ end of the feline coronavirus FIPV 79-1146 genome:
comparison with the genome of porcine coronavirus
TGEV reveals large insertions. Virology 167: 370-376.
42. Kennedy, M., et al. 2001. Deletions in the 7a ORF of
feline coronavirus associated with an epidemic of feline
infectious peritonitis. Vet. Microbiol. 81: 227-234.
43. Vennema, H., et al. 1992. Genomic organization and
expression of the 3′ end of the canine and feline enteric
coronaviruses. Virology 191: 134-140.
44. Vennema, H., et al. 1998. Feline infectious peritonitis
viruses arise by mutation from endemic feline enteric
coronaviruses. Virology 243: 150-157.
45. Yamanaka, M., et al. 1998. Nucleotide sequence of the
inter-structural gene region of feline infectious peri-
tonitis virus. Virus Genes 16: 317-318.
46. Horsburgh, B.C., et al. 1992. Analysis of a 9.6 Kb se-
quence from the 3′ end of canine coronavirus genomic
RNA. J. Gen. Virol. 73: 2849-2862.
47. Rasschaert, D., et al. 1990. Porcine respiratory coro-
navirus diﬀers from transmissible gastroenteritis virus
by a few genomic deletions. J. Gen. Virol. 71: 2599-
2607.
48. Vaughn, E.M., et al. 1995. Sequence comparison of
porcine respiratory coronavirus isolates reveals hetero-
geneity in the S, 3, and 3-1 genes. J. Virol. 69: 3176-
3184.
49. Duarte, M., et al. 1993. Genome organization of
porcine epidemic diarrhoea virus. Adv. Exp. Med.
Biol. 342: 55-60.
50. Duarte, M., et al. 1994. Sequence analysis of the
porcine epidemic diarrhea virus genome between the
nucleocapsid and spike protein genes reveals a poly-
morphic ORF. Virology 198: 466-476.
51. Bridgen, A., et al. 1993. Sequence determination of
the nucleocapsid protein gene of the porcine epidemic
diarrhoea virus conﬁrms that this virus is a coron-
avirus related to human coronavirus 229E and porcine
transmissible gastroenteritis virus. J. Gen. Virol. 74:
1795-1804.
52. Snijder, E.J., et al. 1991. Comparison of the genome
organization of toro- and coronaviruses: evidence for
two nonhomologous RNA recombination events during
Berne virus evolution. Virology 180: 448-452.
53. Weiss, S.R., et al. 1993. The ns 4 gene of mouse hep-
atitis virus (MHV), strain A 59 contains two ORFs
and thus diﬀers from ns 4 of the JHM and S strains.
Arch. Virol. 129: 301-309.
54. Yoo, D., et al. 2000. Primary structure of the
sialodacryoadenitis virus genome: sequence of the
structural-protein region and its application for dif-
ferential diagnosis. Clin. Diagn. Lab. Immunol. 7:
568-573.
55. Abraham, S., et al. 1990. Sequence and expression
analysis of potential nonstructural proteins of 4.9, 4.8,
12.7, and 9.5 kDa encoded between the spike and mem-
brane protein genes of the bovine coronavirus. Virol-
ogy 177: 488-495.
56. Sasseville, A.M., et al. 2002. Sequence of the
3′-terminal end (8.1 Kb) of the genome of porcine
haemagglutinating encephalomyelitis virus: compar-
ison with other haemagglutinating coronaviruses. J.
Gen. Virol. 83: 2411-2416.
57. Mounir, S. and Talbot, P.J. 1993. Human coronavirus
OC43 RNA 4 lacks two open reading frames located
downstream of the S gene of bovine coronavirus. Vi-
rololgy 192: 355-360.
58. Vieler, E., et al. 1996. The region between the M and
S genes of porcine haemagglutinating encephalomyeli-
tis virus is highly similar to human coronavirus OC43.
J. Gen. Virol. 77: 1443-1447.
59. Breslin, J.J., et al. 1999. Sequence analysis of the
turkey coronavirus nucleocapsid protein gene and 3′
untranslated region identiﬁes the virus as a close rel-
ative of infectious bronchitis virus. Virus Res. 65:
187-193.
60. Breslin, J.J., et al. 1999. Sequence analysis of the ma-
trix/nucleocapsid gene region of turkey coronavirus.
Intervirology 42: 22-29.
61. Verbeek, A. and Tijssen, P. 1991. Sequence analysis of
the turkey enteric coronavirus nucleocapsid and mem-
brane protein genes: a close genomic relationship with
bovine coronavirus. J. Gen. Virol. 72: 1659-1666.
62. Boursnell, M.E., et al. 1985. Sequencing of coron-
avirus IBV genomic RNA: three open reading frames
in the 5′ ‘unique’ region of mRNA D. J. Gen. Virol.
66: 2253-2258.
63. Cavanagh, D. and Davis, P.J. 1988. Evolution of avian
coronavirus IBV: sequence of the matrix glycoprotein
gene and intergenic region of several serotypes. J. Vi-
rol. 69: 621-629.
64. Jia, W.N. and Naqi, S.A. 1997. Sequence analysis of
gene 3, gene 4 and gene 5 of avian infectious bronchitis
virus strain CU-T2. Gene 189: 189-193.
65. Lai, M.M. 2003. SARS virus: the beginning of the
unraveling of a new coronavirus. J. Biomed. Sci. 10:
260 Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003
Chow et al.
664-675.
66. Jonassen, C.M., et al. 1998. A common RNA motif
in the 3′ end of the genomes of astroviruses, avian in-
fectious bronchitis virus and an equine rhinovirus. J.
Gen. Virol. 79: 715-718.
67. Lai, M.M. 1992. RNA recombination in animal and
plant viruses. Microbiol. Rev. 56: 61-79.
68. Lai, M.M. 1996. Recombination in large RNA viruses:
coronaviruses. Semin. Virol. 7: 381-388.
69. Luytjes, W., et al. 1988. Sequence of mouse hepati-
tis virus A59 mRNA 2: indications for RNA recom-
bination between coronaviruses and inﬂuenza C virus.
Virology 166: 415-422.
70. Herrewegh, A.A., et al. 1998. Feline coronavirus type
II strains 79-1683 and 79-1146 originate from a double
recombination between feline coronavirus type I and
canine coronavirus. J. Virol. 72: 4508-4514.
71. O’Connor, J.B. and Brain, D.A. 1999. The major
product of porcine transmissible gastroenteritis coro-
navirus gene 3b is an integral membrane glycoprotein
of 31 kDa. Virology 256: 152-161.
72. Vennema, H. 1999. Genetic drift and genetic shift dur-
ing feline coronavirus evolution. Vet. Microbiol. 69:
139-141.
73. Baric, R.S., et al. 1997. Episodic evolution mediates
interspecies transfer of a murine coronavirus. J. Virol.
71: 1946-1955.
74. Kuo, L., et al. 2000. Retargeting of coronavirus
by substitution of the spike glycoprotein ectodomain:
crossing the host cell species barrier. J. Virol. 74:
1393-1406.
75. Sanchez, C.M., et al. 1999. Targeted recombination
demonstrates that the spike gene of transmissible gas-
troenteritis coronavirus is a determinant of its enteric
tropism and virulence. J. Virol. 73: 7607-7618.
76. Lee, C.W. and Jackwood, M.W. 2000. Evidence of
genetic diversity generated by recombination among
avian coronavirus IBV. Arch. Virol. 145: 2135-2148.
77. Rowe, C.L., et al. 1998. Quasispecies development
by high frequency RNA recombination during MHV
persistence. Adv. Exp. Med. Biol. 440: 759-765.
78. Fouchier, R.A., et al. 2003. Aetiology: Koch’s postu-
lates fulﬁlled for SARS virus. Nature 423: 240.
79. Martina, B.E., et al. 2003. Virology: SARS virus
infection of cats and ferrets. Nature 425: 915.
80. Guan, Y., et al. 2003. Isolation and characterization
of viruses related to the SARS coronavirus from ani-
mals in southern China. Science 302: 276-278.
81. Normile, D. and Enserink, M. 2003. SARS in China.
Tracking the roots of a killer. Science 301: 297-299.
82. Koetzner, C.A., et al. 1992. Repair and mutagenesis
of the genome of a deletion mutant of the coronavirus
mouse hepatitis virus by targeted RNA recombination.
J. Virol. 66: 1841-1848.
83. Yount, B., et al. 2003. Reverse genetics with a full-
length infectious cDNA of severe acute respiratory
syndrome coronavirus. Proc. Natl. Acad. Sci. USA
100: 12995-13000.
84. Lin, M., et al. 2003. Association of HLA class I with
severe acute respiratory syndrome coronavirus infec-
tion. BMC Med. Genet. 12: 9.
85. Yam, W.C., et al. 2003. Evaluation of reverse
transcription-PCR assays for rapid diagnosis of severe
acute respiratory syndrome associated with a novel
coronavirus. J. Clin. Microbiol. 41: 4521-4524.
86. Poon, L.L., et al. 2003. Rapid diagnosis of a coro-
navirus associated with severe acute respiratory syn-
drome (SARS). Clin. Chem. 49: 953-955.
87. Poon, L.L., et al. 2003. Early diagnosis of SARS coro-
navirus infection by real time RT-PCR. J. Clin. Virol.
28: 233-238.
88. Shaila, M.S. 2003. Severe acute respiratory syndrome
(SARS): an old virus jumping into a new host or a new
creation. J. Biosci. 28: 359-360.
89. Ng, E.K., et al. 2003. Quantitative analysis and prog-
nostic implication of SARS coronavirus RNA in the
plasma and serum of patients with severe acute respi-
ratory syndrome. Clin. Chem. 49: 1976-1980.
90. Wang, D., et al. 2002. Microarray-based detection
and genotyping of viral pathogens. Proc. Natl. Acad.
Sci. USA 99: 15687-15692.
91. Wang, Y.S., et al. 2003. Analysis of false-positive
associated with antibody tests for SARS-CoV in SLE
patients. Acta Biologiae Exerimentalis Sinica 36: 314-
317. Chinese.
92. Che, X.Y., et al. 2003. Antibody response of patients
with severe acute respiratory syndrome (SARS) to nu-
cleocapsid antigen of SARS-associated coronavirus. J.
First Military Medical Univ. 23: 637-639. Chinese.
93. Holmes, E.C. 1998. Molecular epidemiology and evo-
lution of emerging infectious diseases. Br. Med. Bull.
54: 533-543.
94. Gallagher, T.M. and Buchmeier, M.J. 2001. Coron-
avirus spike proteins in viral entry and pathogenesis.
Virology 279: 371-374.
95. Phillips, J.J., et al. 2002. Murine coronavirus spike
glycoprotein mediates degree of viral spread, inﬂam-
mation, and virus-induced immunopathology in the
central nervous system. Virology 301: 109-120.
96. Hays, J.P. and Myint, S.H. 1998. PCR sequencing of
the spike genes of geographically and chronologically
distinct human coronaviruses 229E. J. Viral. Methods
75: 179-193.
97. Lee, C.W. and Jackwood, M.W. 2001. Origin and evo-
lution of Georgia 98 (GA98), a new serotype of avian
infectious bronchitis virus. Virus Res. 80: 33-39.
98. Guan, Y., et al. 2004. Molecular epidemiology of the
novel coronavirus causing severe acute respiratory syn-
drome (SARS). Lancet 363: 99-104.
Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003 261
Molecular Advances in SARS-CoV
99. Ruan, Y.J., et al. 2003. Comparative full-length
genome sequence analysis of 14 SARS coronavirus iso-
lates and common mutations associated with putative
origins of infection. Lancet 361: 1779-1785.
100. Tsui, S.K., et al. 2003. Coronavirus genomic-sequence
variations and the epidemiology of the severe acute res-
piratory syndrome. N. Engl. J. Med. 349: 187-188.
101. Chiu, R.W., et al. 2003. Molecular epidemiology of
SARS—from Amoy Gardens to Taiwan. N. Engl. J.
Med. 349: 1875-1876.
102. Chim, S.S., et al. 2003. Genomic characterisation of
the severe acute respiratory syndrome coronavirus of
Amoy Gardens outbreak in Hong Kong. Lancet 362:
1807-1808.
103. Zeng, F.Y., et al. 2003. Estimation of the last common
ancestor of severe acute respiratory syndrome (SARS)
coronavirus. N. Engl. J. Med. 349: 2469-2470.
104. Korber, B., et al. 2000. Timing the ancestor of the
HIV-1 pandemic strains. Science 288: 1789-1796.
105. Tang, X., et al. 2003. Measurement of subgroups of
peripheral blood T lymphocytes in patients with se-
vere acute respiratory syndrome and its clinical signif-
icance. Chin. Med. J. 116: 827-830.
106. Li, G., et al. 2003. Proﬁle of speciﬁc antibodies to the
SARS-associated coronavirus. N. Engl. J. Med. 349:
508-509.
107. Chen, K.H., et al. 2003. Determination of SARS coro-
navirus in patients with suspected SARS. Emerg. In-
fect. Dis. In press.
108. de Herdt, P., et al. 2001. Infectious bronchitis serol-
ogy in broilers and broiler breeders: corrections be-
tween antibody titers and performance in vaccinated
ﬂocks. Avian Dis. 45: 612-619.
109. Cavanagh, D., et al. 1986. Coronavirus IBV: virus re-
taining spike glycopolypeptide S2 but not S1 is unable
to induce virus-neutralizing or haemagglutination-
inhibiting antibody, or induce chicken tracheal pro-
tection. J. Gen. Virol. 67: 1435-1442.
110. de Groot, A.S. 2003. How the SARS vaccine eﬀort can
learn from HIV-speeding towards the future, learning
from the past. Vaccine 21: 4095-4104.
111. Anand, K., et al. 2003. Coronavirus main proteinase
(3CLpro) structure: basis for design of anti-SARS
drugs. Science 300: 1763-1767.
112. Campanacci, V., et al. 2003. Structural genomics of
the SARS coronavirus: cloning, expression, crystal-
lization and preliminary crystallographic study of the
Nsp9 protein. Acta Crystallogr. D. Biol. Crystallogr.
59: 1628-1631.
113. Chou, K.C., et al. 2003. Binding mechanism of coron-
avirus main proteinase with ligands and its implication
to drug design against SARS. Biochem. Biophys. Res.
Commun. 308: 148-151.
114. Fan, K., et al. 2004. Biosynthesis, puriﬁcation and
substrate speciﬁcity of SARS coronavirus 3C-like pro-
teinase. J. Biol. Chem. 279. In press.
115. Yang, H., et al. 2003. The crystal structures of severe
acute respiratory syndrome virus main protease and
its complex with an inhibitor. Proc. Natl. Acad. Sci.
USA 100: 13190-13195.
116. von Grotthuss, M., et al. 2003. mRNA cap-1 methyl-
transferase in the SARS genome. Cell 113: 701-702.
117. Knudsen, T.B., et al. 2003. Severe acute respira-
tory syndrome—a new coronavirus from the Chinese
dragon’s lair. Scand. J. Immunol. 58: 277-284.
This work was supported by Research Grant
Council Grant HKU 7553/03M and The University
of Hong Kong.
262 Geno., Prot. & Bioinfo. Vol. 1 No. 4 November 2003
